ES2995196T3 - Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm - Google Patents
Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm Download PDFInfo
- Publication number
- ES2995196T3 ES2995196T3 ES20175739T ES20175739T ES2995196T3 ES 2995196 T3 ES2995196 T3 ES 2995196T3 ES 20175739 T ES20175739 T ES 20175739T ES 20175739 T ES20175739 T ES 20175739T ES 2995196 T3 ES2995196 T3 ES 2995196T3
- Authority
- ES
- Spain
- Prior art keywords
- covid
- coronavirus
- atr
- sars
- stage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20175739.0A EP3912623B1 (en) | 2020-05-20 | 2020-05-20 | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2995196T3 true ES2995196T3 (en) | 2025-02-07 |
Family
ID=70802645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20175739T Active ES2995196T3 (en) | 2020-05-20 | 2020-05-20 | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230241014A1 (https=) |
| EP (2) | EP3912623B1 (https=) |
| JP (1) | JP2023526836A (https=) |
| KR (1) | KR20230013077A (https=) |
| CN (1) | CN116635022A (https=) |
| AU (1) | AU2021277517A1 (https=) |
| BR (1) | BR112022023013A2 (https=) |
| CA (1) | CA3178137A1 (https=) |
| ES (1) | ES2995196T3 (https=) |
| MX (1) | MX2022014561A (https=) |
| WO (1) | WO2021234097A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3973960B1 (en) | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| AU2021206684B2 (en) | 2020-01-10 | 2024-01-18 | Immuneering Corporation | MEK inhibitors and therapeutic uses thereof |
| WO2023084489A1 (en) * | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| EP4186500A1 (en) * | 2021-11-24 | 2023-05-31 | Atriva Therapeutics GmbH | Mek inhibitors for the prevention and treatment of long covid syndrome |
| WO2024042050A1 (en) * | 2022-08-22 | 2024-02-29 | Atriva Therapeutics Gmbh | Use of mek1/2 inhibitors to synergistically potentiate the antiviral effect of direct-acting anti-coronavirus drugs |
| US20240165099A1 (en) * | 2022-09-30 | 2024-05-23 | 60 Degrees Pharmaceuticals Llc | Methods for the treatment and prevention of diseases or infections with mcp-1 involvement by administration of tafenoquine |
| CN116270588B (zh) * | 2022-12-26 | 2025-07-25 | 中国科学技术大学 | Mek1/2抑制剂u0126在治疗car t细胞引起的crs中的应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1420778B1 (en) * | 2001-03-06 | 2006-11-22 | Dorian Bevec | Use of mek inhibitors for treating virus induced hemorrhagic shock or fever |
| EP3973960B1 (en) * | 2017-10-17 | 2025-09-03 | Atriva Therapeutics GmbH | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
-
2020
- 2020-05-20 EP EP20175739.0A patent/EP3912623B1/en active Active
- 2020-05-20 ES ES20175739T patent/ES2995196T3/es active Active
-
2021
- 2021-05-20 CN CN202180059642.7A patent/CN116635022A/zh active Pending
- 2021-05-20 JP JP2022570454A patent/JP2023526836A/ja active Pending
- 2021-05-20 CA CA3178137A patent/CA3178137A1/en active Pending
- 2021-05-20 KR KR1020227044294A patent/KR20230013077A/ko active Pending
- 2021-05-20 AU AU2021277517A patent/AU2021277517A1/en active Pending
- 2021-05-20 EP EP21731684.3A patent/EP4153159A1/en active Pending
- 2021-05-20 US US17/999,185 patent/US20230241014A1/en active Pending
- 2021-05-20 MX MX2022014561A patent/MX2022014561A/es unknown
- 2021-05-20 WO PCT/EP2021/063485 patent/WO2021234097A1/en not_active Ceased
- 2021-05-20 BR BR112022023013A patent/BR112022023013A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230241014A1 (en) | 2023-08-03 |
| BR112022023013A2 (pt) | 2022-12-20 |
| AU2021277517A1 (en) | 2022-12-08 |
| EP3912623A1 (en) | 2021-11-24 |
| CA3178137A1 (en) | 2021-11-25 |
| CN116635022A (zh) | 2023-08-22 |
| KR20230013077A (ko) | 2023-01-26 |
| EP4153159A1 (en) | 2023-03-29 |
| EP3912623B1 (en) | 2024-07-31 |
| JP2023526836A (ja) | 2023-06-23 |
| EP3912623C0 (en) | 2024-07-31 |
| WO2021234097A1 (en) | 2021-11-25 |
| MX2022014561A (es) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2995196T3 (en) | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm | |
| US11633418B2 (en) | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome | |
| ES2748556T3 (es) | Terapia de desoxinucleósidos para enfermedades causadas por grupos de nucleótidos desequilibrados incluyendo síndromes de agotamiento de ADN mitocondrial | |
| US12167994B2 (en) | Vidofludimus for use in the treatment or prevention of viral diseases | |
| CN113679726B (zh) | 丹参提取物和醌类化合物在抗冠状病毒中的应用 | |
| Jordan et al. | Antiviral efficacy of a respiratory syncytial virus (RSV) fusion inhibitor in a bovine model of RSV infection | |
| US20240093198A1 (en) | Tgf-beta therapeutics for age disease | |
| KR20210035339A (ko) | 바이러스 감염을 치료하기 위한 티아졸리드 화합물 | |
| KR20150005526A (ko) | 바이러스 질환을 치료하기 위한 성분 및 방법 | |
| ES2937145T3 (es) | Azelastina como tratamiento antiviral | |
| CN112618547A (zh) | 一种喹啉类化合物在制备抗冠状病毒制剂中的应用 | |
| BR112020010878A2 (pt) | tratamento de rsv com produto de combinação | |
| CN115873942A (zh) | Trim35作为抗腺病毒感染治疗药物的新靶点及其应用 | |
| JP2023521162A (ja) | 重症急性呼吸器症候群を治療する方法 | |
| EA051538B1 (ru) | Ингибиторы mek для лечения или предупреждения коронавирусных инфекций и/или цитокинового шторма при covid-19 | |
| EP4186500A1 (en) | Mek inhibitors for the prevention and treatment of long covid syndrome | |
| US20240165096A1 (en) | Anti Viral Therapy | |
| ES3010311T3 (en) | Mouse minute virus for treatment of tp53/p53 modified forms of cancer | |
| HK40062780A (en) | Vidofludimus for use in the treatment or prevention of viral diseases | |
| CN119097711A (zh) | Ape1抑制剂在制备治疗鼻窦炎药物中的应用 | |
| CN121868284A (zh) | 用于防治新型冠状病毒感染的药物组合物 | |
| CN121445739A (zh) | Pha-767491作为h3n2亚型猪流感病毒复制抑制剂的应用 | |
| WO2020216349A1 (zh) | 一种肠道病毒抑制剂 |